Research graph
References from Precision Oncology in Breast Cancer Surgery. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Gene expression profiling predicts clinical outcome of breast cancer
10.1038/415530a · 2002 · External reference
Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades
10.1001/jamaoncol.2017.1261 · 2017 · External reference
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
10.1200/jco.1998.16.8.2672 · 1998 · External reference
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
10.1200/jco.2005.04.1665 · 2006 · External reference
Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial
10.1001/jamaoncol.2020.2535 · 2020 · External reference
Breast and ovarian cancer
10.1056/nejmra012284 · 2003 · External reference
Unresolved reference
External reference
Comprehensive molecular portraits of human breast tumours
10.1038/nature11412 · 2012 · External reference
Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?
10.1200/jco.2012.46.9403 · 2013 · External reference
Multigene panel testing in oncology practice: how should we respond?
10.1001/jamaoncol.2015.28 · 2015 · External reference
Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology
10.1200/jco.2013.49.7388 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?
10.1200/jco.18.01631 · 2019 · External reference
Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer
10.1200/jco.19.02190 · 2020 · External reference
Unresolved reference
External reference
I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer
10.1007/s12609-019-00334-2 · 2019 · External reference
Unresolved reference
2019 · External reference
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
10.1056/nejmoa2105215 · 2021 · External reference
Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study
10.21037/atm-21-7006 · 2022 · External reference
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
10.1016/j.ccell.2022.05.005 · 2022 · External reference
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS)
10.1200/jco.2023.41.16_suppl.102 · 2023 · External reference
Changes in surgical management of the axilla over 11 years - report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial
10.1245/s10434-023-13759-y · 2023 · External reference
Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
10.1002/bjs.10986 · 2018 · External reference
Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection
10.1200/jco.2015.64.0094 · 2016 · External reference
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial
10.1001/jamasurg.2019.5410 · 2020 · External reference
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
10.1016/s1470-2045(17)30777-5 · 2018 · External reference
Breast conservation surgery and mastectomy have similar locoregional recurrence following neoadjuvant chemotherapy: results from 1,462 patients on the prospective, randomized I-SPY2 trial
10.1097/sla.0000000000005968 · 2023 · External reference
Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update
10.1200/jco.22.00069 · 2022 · External reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · 2022 · External reference
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial
10.1001/jamaoncol.2019.6650 · 2020 · External reference
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
10.1016/s1470-2045(17)30716-7 · 2018 · External reference
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
10.1093/annonc/mdt182 · 2013 · External reference
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival
10.2214/ajr.184.6.01841774 · 2005 · External reference
Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial
10.1148/radiol.2018180273 · 2018 · External reference
MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer
10.1002/jso.25663 · 2019 · External reference
The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response
10.1080/0284186x.2020.1797161 · 2020 · External reference
Locoregional management after neoadjuvant chemotherapy
10.1200/jco.19.02576 · 2020 · External reference
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
10.1016/s1470-2045(22)00613-1 · 2022 · External reference
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study
10.1007/s10549-023-06899-y · 2023 · External reference
A careful reassessment of anthracycline use in curable breast cancer
10.1038/s41523-021-00342-5 · 2021 · External reference
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
10.1200/jco.2006.06.5391 · 2006 · External reference
Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
10.1200/jco.2016.71.4147 · 2017 · External reference
Unresolved reference
2023 · External reference
Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial
10.1001/jamaoncol.2020.2295 · 2020 · External reference
Circulating tumour cells in non-metastatic breast cancer: a prospective study
10.1016/s1470-2045(12)70209-7 · 2012 · External reference
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
10.1056/nejmoa040766 · 2004 · External reference
RNA-seq of circulating tumor cells in stage II-III breast cancer
10.1245/s10434-018-6540-4 · 2018 · External reference
Circulating tumor cell transcriptomics as biopsy surrogates in metastatic breast cancer
10.1245/s10434-021-11135-2 · 2022 · External reference
A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the parsortix((R)) PC1 system
10.3390/cancers14215238 · 2022 · External reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · 2013 · External reference
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
10.1038/ncomms9760 · 2015 · External reference
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
10.1126/scitranslmed.aab0021 · 2015 · External reference
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
10.1126/scitranslmed.aax7392 · 2019 · External reference
Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer
10.1158/1078-0432.ccr-19-3005 · 2020 · External reference
Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
10.1200/jco.22.00908 · 2022 · External reference
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
10.1158/1078-0432.ccr-18-3663 · 2019 · External reference
Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse
10.1200/po.22.00148 · 2022 · External reference
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
10.1016/j.annonc.2022.11.005 · 2023 · External reference
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
10.1016/s1470-2045(20)30444-7 · 2020 · External reference
Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update
10.1200/jco.23.00638 · 2023 · External reference
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
10.1016/j.annonc.2020.11.007 · 2021 · External reference
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
10.1016/j.ccell.2023.04.008 · 2023 · External reference
The current status of the clinical utility of liquid biopsies in cancer
10.1080/14737159.2019.1664290 · 2019 · External reference
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
10.1200/jco.22.00338 · 2022 · External reference
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
10.1016/j.annonc.2020.11.011 · 2021 · External reference
10.1200/jco.2022.40.16_suppl.1006
10.1200/jco.2022.40.16_suppl.1006 · 2022 · External reference
Global guidelines for breast cancer screening: A systematic review
10.1016/j.breast.2022.04.003 · 2022 · External reference
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
10.1016/s1470-2045(13)70598-9 · 2014 · External reference
Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
2017 · External reference
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
10.1038/ng.3242 · 2015 · External reference
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
10.1038/ng.2563 · 2013 · External reference
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
10.1093/jnci/djw290 · 2017 · External reference
The WISDOM Study: breaking the deadlock in the breast cancer screening debate
10.1038/s41523-017-0035-5 · 2017 · External reference
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model
10.7326/0003-4819-148-5-200803040-00004 · 2008 · External reference
Unresolved reference
External reference
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
10.1126/science.abb9601 · 2020 · External reference
A review of AI-based radiomics and computational pathology approaches in triple-negative breast cancer: current applications and perspectives
10.1016/j.clbc.2023.06.004 · 2023 · External reference
Blood-based multi-cancer detection using a novel variant calling assay (DEEPGEN(TM)): early clinical results
10.3390/cancers13164104 · 2021 · External reference
DEEPGEN(TM)-a novel variant calling assay for low frequency variants
10.3390/genes12040507 · 2021 · External reference
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study
10.1148/radiol.222733 · 2023 · External reference
Epidemiology of ductal carcinoma in situ
10.1093/jncimonographs/lgq027 · 2010 · External reference
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
10.1093/jnci/djr027 · 2011 · External reference
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
10.1136/bmjopen-2018-026797 · 2019 · External reference
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort
10.1158/2767-9764.crc-22-0263 · 2022 · External reference
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
10.1038/s41523-021-00267-z · 2021 · External reference
Rethinking screening for breast cancer and prostate cancer
10.1001/jama.2009.1498 · 2009 · External reference
